Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Clinical trial NCT01116232 · TERMINATED

Trial details

NCT number: NCT01116232
Sponsor: Barbara Ann Karmanos Cancer Institute
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Myeloproliferative Disorders Graft Versus Host Disease Leukemia Lymphoma Lymphoproliferative Disorder Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms

Start date: 2010-08-01
Primary completion: 2013-05-01
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.